[Action of pyrithioxine combined with a vasodilator in patients with cerebral arteriosclerosis].
D000368:Aged; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D002537:Intracranial Arteriosclerosis / Q000188:drug therapy*; D008297:Male; D000432:Methanol / Q000009:adverse effects / Q000627:therapeutic use*; D009461:Neurologic Manifestations; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D011736:Pyridoxine / Q000009:adverse effects / Q000627:therapeutic use*; D013440:Sulfides / Q000009:adverse effects / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*
D004338:Drug Combinations; D011725:Pyridines; D013440:Sulfides; D014665:Vasodilator Agents; D011736:Pyridoxine; D000432:Methanol
Ação da piritioxina associada a um vasodilatador em pacientes com arterioesclerose cerebral.